Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
704 studies found for:    Open Studies | "Lymphoma, Non-Hodgkin"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Lymphoma, Non-Hodgkin"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Procedure: Stem cell infusion;   Procedure: TLI;   Drug: Anti-thymocyte globulin;   Drug: Solumedrol;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
2 Recruiting A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Vincristine;   Drug: Idarubicin;   Drug: Dexamethasone
3 Recruiting Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Placebo
4 Not yet recruiting A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: TAK-659;   Drug: Bendamustine;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Lenalidomide;   Drug: Ibrutinib
5 Recruiting BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Busulfan;   Drug: Etoposide;   Drug: Bendamustine
6 Recruiting Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: ABP 798;   Drug: Rituximab
7 Recruiting Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Bendamustine;   Drug: Prednisone
8 Recruiting A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: LAM-002A
9 Recruiting Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY1862864
10 Recruiting A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: CC-122
11 Recruiting GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Obinutuzumab and Pixantrone
12 Not yet recruiting Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Cytokine-induced killer cells (CIK)
13 Recruiting ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: ESHAP-Imatinib
14 Recruiting Phase III Copanlisib in Rituximab-refractory iNHL
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: BAY No. 80 6946;   Drug: Placebo
15 Recruiting BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BI 836826
16 Not yet recruiting Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin's
Interventions: Drug: Obinutuzumab;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin
17 Recruiting Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Condition: Lymphoma,Non-Hodgkin
Interventions: Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab
18 Recruiting A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non Hodgkin
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Rituximab
19 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
20 Recruiting Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma
Condition: Lymphoma, Non-Hodgkin;Hodgkin Disease
Interventions: Drug: R-CHOP/CHOPE or ABVD chemotherapy regimen;   Drug: R-CDOP/CDOPE or DBVD chemotherapy regimen

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.